MB-105 not checked

March Biosciences Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“MB-105 is a CAR T-cell therapy that consists of autologous T-cells that express a CD5 CAR.”In the company’s words, NCT06534060 on ClinicalTrials.gov
Tested for
Lymphoma, T-Cell
Main trialPhase 2
“This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.”In the company’s words, NCT06534060 on ClinicalTrials.gov

Other drugs for Lymphoma, T-Cell

All 52 drugs for Lymphoma, T-Cell

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Feb 2028 MB-105 in Patients With CD5 Positive T-cell Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MB-105

Following is part of Solo: you see every change to MB-105 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in